HUTCHMED (China) Limited (HCM)
USD 15.0
(1.35%)
USD 15.0
(1.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 25.52 Million USD | 106.36% |
| 2022 | -401.1 Million USD | -21.82% |
| 2021 | -207.95 Million USD | -80.04% |
| 2020 | -182.88 Million USD | -35.34% |
| 2019 | -135.13 Million USD | -64.68% |
| 2018 | -82.05 Million USD | -65.76% |
| 2017 | -49.5 Million USD | -14.1% |
| 2016 | -43.39 Million USD | -509.24% |
| 2015 | -7.15 Million USD | -22.0% |
| 2014 | -17.17 Million USD | -469.2% |
| 2013 | 1.58 Million USD | 123.28% |
| 2012 | -6.79 Million USD | -166.59% |
| 2011 | 10.19 Million USD | 276.99% |
| 2010 | 2.37 Million USD | 1823.32% |
| 2009 | -46.89 Thousand USD | 101.49% |
| 2008 | -9.57 Million USD | -68.94% |
| 2007 | -5.92 Million USD | -130.17% |
| 2006 | -2.51 Million USD | 32.39% |
| 2005 | -3.41 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -10.63 Million USD | 76.07% |
| 2024 Q2 | -10.63 Million USD | 0.0% |
| 2023 Q2 | 57.73 Million USD | 0.0% |
| 2023 Q4 | -44.44 Million USD | 0.0% |
| 2023 FY | - USD | 106.36% |
| 2023 Q1 | 57.73 Million USD | 155.87% |
| 2023 Q3 | -44.44 Million USD | -176.98% |
| 2022 FY | - USD | -21.82% |
| 2022 Q4 | -103.32 Million USD | 0.0% |
| 2022 Q3 | -103.32 Million USD | 46.29% |
| 2022 Q2 | -192.37 Million USD | -100.0% |
| 2022 Q1 | -96.18 Million USD | -19.33% |
| 2021 Q4 | -80.6 Million USD | 10.89% |
| 2021 FY | - USD | -80.04% |
| 2021 Q3 | -90.45 Million USD | -12.32% |
| 2021 Q1 | -63.2 Million USD | -79.6% |
| 2021 Q2 | -80.53 Million USD | -27.43% |
| 2020 Q4 | -35.18 Million USD | 39.0% |
| 2020 FY | - USD | -35.34% |
| 2020 Q2 | -45.67 Million USD | -40.57% |
| 2020 Q1 | -32.49 Million USD | -132.27% |
| 2020 Q3 | -57.68 Million USD | -26.29% |
| 2019 Q1 | -36.05 Million USD | 6.18% |
| 2019 Q2 | -35.96 Million USD | 0.25% |
| 2019 FY | - USD | -64.68% |
| 2019 Q3 | -34.71 Million USD | 3.47% |
| 2019 Q4 | 100.67 Million USD | 390.02% |
| 2018 Q3 | -13.91 Million USD | 44.41% |
| 2018 Q2 | -25.03 Million USD | -0.04% |
| 2018 Q1 | -25.02 Million USD | 29.46% |
| 2018 FY | - USD | -65.76% |
| 2018 Q4 | -38.42 Million USD | -176.16% |
| 2017 FY | - USD | -14.1% |
| 2017 Q3 | -18.04 Million USD | -22.3% |
| 2017 Q4 | -35.46 Million USD | -96.58% |
| 2017 Q1 | -7.37 Million USD | 50.04% |
| 2017 Q2 | -14.75 Million USD | -100.0% |
| 2016 Q1 | -7.41 Million USD | -1084.33% |
| 2016 FY | - USD | -509.24% |
| 2016 Q2 | -7.41 Million USD | 0.0% |
| 2016 Q4 | -14.76 Million USD | 0.0% |
| 2016 Q3 | -14.76 Million USD | -99.22% |
| 2015 Q3 | -13.14 Million USD | -3142.13% |
| 2015 FY | - USD | -22.0% |
| 2015 Q4 | 753 Thousand USD | 105.73% |
| 2015 Q2 | 432 Thousand USD | 0.0% |
| 2015 Q1 | 432 Thousand USD | -97.89% |
| 2014 FY | - USD | -469.2% |
| 2014 Q4 | 20.48 Million USD | 202.5% |
| 2014 Q2 | -1.89 Million USD | 0.0% |
| 2014 Q1 | -1.89 Million USD | 81.01% |
| 2014 Q3 | -19.98 Million USD | -952.28% |
| 2013 Q3 | 2.14 Million USD | 197.17% |
| 2013 Q1 | -2.2 Million USD | 48.78% |
| 2013 Q2 | -2.2 Million USD | 0.0% |
| 2013 FY | - USD | 123.28% |
| 2013 Q4 | -10 Million USD | -566.64% |
| 2012 FY | - USD | -166.59% |
| 2012 Q3 | -4.3 Million USD | 0.0% |
| 2012 Q4 | -4.3 Million USD | 0.0% |
| 2011 FY | - USD | 276.99% |
| 2010 FY | - USD | 1823.32% |
| 2009 FY | - USD | 101.49% |
| 2008 FY | - USD | -68.94% |
| 2007 FY | - USD | -130.17% |
| 2006 FY | - USD | 32.39% |
| 2005 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | -150.1 Million USD | 117.006% |
| Theratechnologies Inc. | -10.31 Million USD | 347.537% |
| Safety Shot Inc | -12.18 Million USD | 309.5% |
| Cosmos Health Inc. | -17.06 Million USD | 249.621% |
| Cronos Group Inc. | -72.14 Million USD | 135.382% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 102.76% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 170.75% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 29.15% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 894.011% |
| ProPhase Labs, Inc. | -14.82 Million USD | 272.172% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 664.155% |
| Dynavax Technologies Corporation | 9.66 Million USD | -164.101% |
| Radius Health, Inc. | 38.31 Million USD | 33.365% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 1185.831% |
| Alvotech | -484.86 Million USD | 105.265% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 767.5% |
| Alpha Teknova, Inc. | -25.53 Million USD | 199.957% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 116.07% |
| SCYNEXIS, Inc. | 73.47 Million USD | 65.258% |
| Harrow Health, Inc. | 9.72 Million USD | -162.553% |
| Biofrontera Inc. | -18.45 Million USD | 238.341% |
| DURECT Corporation | -24.68 Million USD | 203.419% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 74.02% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 76.648% |
| OptiNose, Inc. | -15.55 Million USD | 264.136% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 2.81% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -2059.729% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 3691.194% |
| SIGA Technologies, Inc. | 84.15 Million USD | 69.667% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -3043.842% |
| Shineco, Inc. | -26.55 Million USD | 196.136% |
| Phibro Animal Health Corporation | 84.6 Million USD | 69.828% |
| Procaps Group S.A. | 104.02 Million USD | 75.46% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 403.869% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 805.656% |
| Viatris Inc. | 3.51 Billion USD | 99.274% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 767.5% |
| Rockwell Medical, Inc. | -4.69 Million USD | 643.843% |
| Incannex Healthcare Limited | -18.5 Million USD | 237.959% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 2622.53% |
| Tilray Brands, Inc. | -72.84 Million USD | 135.045% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 91.721% |
| PetIQ, Inc. | 81.48 Million USD | 68.672% |
| Silver Spike Investment Corp. | 7.34 Million USD | -247.788% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 93.865% |
| Journey Medical Corporation | 1.92 Million USD | -1228.891% |
| Alimera Sciences, Inc. | 7.27 Million USD | -250.852% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 706.096% |
| Assertio Holdings, Inc. | -222.44 Million USD | 111.476% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 739.695% |
| Embecta Corp. | 245.4 Million USD | 89.597% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 227.444% |
| Procaps Group, S.A. | 104.02 Million USD | 75.46% |
| PainReform Ltd. | -9.56 Million USD | 366.778% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 117.119% |
| Hempacco Co., Inc. | -12.77 Million USD | 299.855% |
| Talphera, Inc. | -9.84 Million USD | 359.378% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 84.329% |
| Alvotech | -484.86 Million USD | 105.265% |
| Lantheus Holdings, Inc. | 491 Million USD | 94.801% |
| Kamada Ltd. | 21.53 Million USD | -18.547% |
| Indivior PLC | 66 Million USD | 61.321% |
| Currenc Group, Inc. | -1.9 Million USD | 1443.173% |
| Evoke Pharma, Inc. | -7.29 Million USD | 450.068% |
| Flora Growth Corp. | -45.87 Million USD | 155.653% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 227.444% |
| Evolus, Inc. | -41.81 Million USD | 161.057% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 89.428% |
| Akanda Corp. | -27.73 Million USD | 192.04% |